SOPHiA GENETICS SA (NASDAQ:SOPH) Sees Large Increase in Short Interest

SOPHiA GENETICS SA (NASDAQ:SOPH) saw a large increase in short interest during the month of October. As of October 31st, there was short interest totalling 24,100 shares, an increase of 66.2% from the October 15th total of 14,500 shares. Currently, 0.1% of the company’s shares are short sold. Based on an average trading volume of 43,100 shares, the days-to-cover ratio is presently 0.6 days.

Analyst Ratings Changes

Several equities research analysts have issued reports on SOPH shares. Royal Bank of Canada decreased their price objective on shares of SOPHiA GENETICS from $8.00 to $7.00 and set an “outperform” rating for the company in a research note on Wednesday, August 7th. Morgan Stanley lowered SOPHiA GENETICS from an “overweight” rating to an “equal weight” rating and dropped their price target for the company from $10.00 to $5.00 in a research report on Wednesday, August 7th.

SOPHiA GENETICS Stock Down 7.3 %

Shares of SOPHiA GENETICS stock traded down $0.29 during midday trading on Wednesday, reaching $3.70. 7,141 shares of the company’s stock traded hands, compared to its average volume of 67,266. The company has a market cap of $241.91 million, a price-to-earnings ratio of -3.41 and a beta of 1.03. SOPHiA GENETICS has a 52 week low of $2.70 and a 52 week high of $7.37. The company’s 50 day simple moving average is $3.66 and its 200 day simple moving average is $4.19. The company has a debt-to-equity ratio of 0.12, a quick ratio of 3.59 and a current ratio of 3.80.

SOPHiA GENETICS (NASDAQ:SOPH) last released its quarterly earnings results on Tuesday, November 5th. The company reported ($0.28) EPS for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.04). SOPHiA GENETICS had a negative net margin of 110.71% and a negative return on equity of 55.06%. The firm had revenue of $15.85 million during the quarter, compared to the consensus estimate of $15.90 million. During the same period in the prior year, the business earned ($0.21) EPS. Equities analysts expect that SOPHiA GENETICS will post -0.95 earnings per share for the current fiscal year.

Institutional Trading of SOPHiA GENETICS

A number of hedge funds have recently bought and sold shares of the stock. Banque Cantonale Vaudoise lifted its position in shares of SOPHiA GENETICS by 300.0% in the 2nd quarter. Banque Cantonale Vaudoise now owns 12,000 shares of the company’s stock worth $55,000 after acquiring an additional 9,000 shares during the period. Green Alpha Advisors LLC bought a new position in shares of SOPHiA GENETICS during the 3rd quarter worth about $79,000. Federated Hermes Inc. increased its stake in SOPHiA GENETICS by 57.5% in the second quarter. Federated Hermes Inc. now owns 63,000 shares of the company’s stock valued at $289,000 after acquiring an additional 23,000 shares during the period. Edmond DE Rothschild Holding S.A. raised its position in SOPHiA GENETICS by 5.0% in the first quarter. Edmond DE Rothschild Holding S.A. now owns 203,334 shares of the company’s stock worth $1,002,000 after purchasing an additional 9,700 shares in the last quarter. Finally, Akre Capital Management LLC bought a new stake in shares of SOPHiA GENETICS in the 1st quarter valued at approximately $1,418,000. 31.59% of the stock is owned by institutional investors.

About SOPHiA GENETICS

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific.